Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model
- 21 April 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (5)
- https://doi.org/10.1128/aac.00084-20
Abstract
Fluoroquinolones are reported to possess immunomodulatory activity; hence, a novel benzoquinolizine fluoroquinolone, levonadifloxacin, was evaluated in lipopolysaccharide-stimulated human whole-blood (HWB) and mouse acute lung injury (ALI) models. Levonadifloxacin significantly mitigated the inflammatory responses in an HWB assay through inhibition of proinflammatory cytokines and in the ALI model by lowering lung total white blood cell count, myeloperoxidase, and cytokine levels. The immunomodulatory effect of levonadifloxacin, along with promising antibacterial activity, is expected to provide clinical benefits in the treatment of infections.This publication has 23 references indexed in Scilit:
- Classical dendritic cells regulate acute lung inflammation and injury in mice with lipopolysaccharide‑induced acute respiratory distress syndromeInternational Journal of Molecular Medicine, 2019
- Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult SubjectsAntimicrobial Agents and Chemotherapy, 2018
- Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatmentCritical Care, 2017
- Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosisWorld Journal of Gastroenterology, 2015
- β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2014
- New Markers: Urine Xanthine Oxidase and Myeloperoxidase in the Early Detection of Urinary Tract InfectionDisease Markers, 2014
- Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated ViewMediators of Inflammation, 2013
- In Vitro Activity of the Quinolone WCK 771 against Recent U.S. Hospital and Community-Acquired Staphylococcus aureus Pathogens with Various Resistance TypesAntimicrobial Agents and Chemotherapy, 2009
- Immunomodulatory Activities of FluoroquinolonesInfection, 2005
- Activity of the new quinolone WCK 771 against pneumococciClinical Microbiology & Infection, 2005